Published date: 13 December 2019
Last edited date: 14 September 2021
This notice was replaced on 21 October 2021
This notice does not contain the most up-to-date information about this procurement. The most recent notice is:
Future opportunity (published 21 October 2021)
Closed future opportunity - This means that a potential contract has passed its approach to market date. A buyer can choose to consider any supplier interest or convert this notice into an opportunity ready for live procurement.
Contract summary
Industry
Blood coagulants - 33141530
Location of contract
United Kingdom, Isle of Man, Channel Islands
Value of contract
£45,000,000
Procurement reference
CM/PHS/19/5576
Published date
13 December 2019
Approach to market date
1 November 2021
Contract start date
1 March 2022
Contract end date
28 February 2023
Procedure type
Open procedure (above threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements above the relevant contract value threshold.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
No
Description
Recombinant Factor IX
More information
Spend profile
| Financial year | Budget |
|---|---|
| 2021/2022 | £3,750,000 |
| 2022/2023 | £41,250,000 |
About the buyer
Contact name
Karen Bell
Address
Commercial Medicines Unit - NHS England
2nd Floor, Rutland House
Runcorn
WA7 2ES
England
Share this notice
All content is available under the
